pSivida expands BrachySil study program

4 June 2006

Australian bionanotechnology company pSivida says it has broadened the scope of a Phase IIb trial of BrachySil (32-P BioSilicon), used in the treatment of inoperable liver cancer, to new research centers in the Philippines and Taiwan.

The study, which is also being undertaken at sites in Singapore, Vietnam and Malaysia, is designed to determining the optimal dose of the drug for use in the treatment of patients with hepatocellular carcinoma. Enrolled subjects will be evaluated for up to 12 months after the trial ends, with primary endpoints being defined as patient safety and tumor response.

The firm added that a Phase IIa trial, initiated in June 2004, showed that the product was safe and well tolerated in patients suffering from this type of cancer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >

Today's issue

Company Spotlight

Ironwood is a US-based biotech advancing a pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation ((IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others.